undamentalytics Newsletter
Sign in

Coya Therapeutics, Inc. cash flow statement

In fiscal 2025, Coya Therapeutics, Inc.'s operations generated −$10.7m of cash.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−7−11−10−11−16
Depreciation and amortisation00000
Stock-based pay01345
Shares issued——1420—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ACRS vs COYAADAG vs COYAAPLM vs COYA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Coya Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Coya Therapeutics, Inc.